Indeed, T-DXd treatment potentiated the release of exosomal DNA from cancer cells, and these exosomes effectively activated DCs, leading to the upregulation of HLA-DR and a trend toward increased CD86 expression, although the latter did not reach statistical significance (p = 0.0536) (Fig. 6G, S3, H). The gene discussed is CD86; the disease is cancer.